beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease
about
Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal modelsTransthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Vitamin A and Alzheimer's diseaseCerebrospinal fluid biomarkers of Alzheimer’s diseaseThe coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathwayApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyStructural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrilsBiomarkers of Alzheimer's diseaseSoluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's diseaseP3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brainCerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's diseaseVitamin D and Alzheimer's Disease: Neurocognition to TherapeuticsTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsDense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentricStructural investigation of the C-terminal catalytic fragment of presenilin 1Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapyPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyChemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumabCharacterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.Structural Mechanism of the Interaction of Alzheimer Disease Aβ Fibrils with the Non-steroidal Anti-inflammatory Drug (NSAID) Sulindac SulfideAtomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease miceCholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation.Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease.Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40.Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding.Vascular pathology in the aged human brainAmyloid and lipids in the pathology of Alzheimer disease.Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid depositsNeuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia.Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierThe blood-brain barrier and microvascular water exchange in Alzheimer's disease.Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragmentsThe biochemical aftermath of anti-amyloid immunotherapy.
P2860
Q21135564-FB409E59-AF0B-44F8-80E2-BA0EB65E1EDBQ21202832-77C73037-FF55-407B-8C75-64EF007211F5Q22242414-73F1C46A-12F5-4E60-A50E-F26EC26DC152Q22252572-7E89F7F0-4B2F-49E4-B81A-3B06518CEC11Q24294387-E5BC0410-BFDF-45B3-81E5-E728471DD32DQ24604376-EF03A166-02D9-45B8-BAD6-04BBC5D44E7FQ24631702-AAD5F619-E8D2-4B9B-B101-0F48AE7C295EQ24650667-1B589C48-4AA2-4917-A9A0-52D26AF709E8Q24670696-5578A5A3-82F9-4850-ABB9-8E38F8531D25Q24673212-2C3166FA-FFF7-45A2-837A-3D2AEAAF72D8Q24682442-755B7466-D8F7-48F0-9DB1-A7C51D0B3610Q26782403-1A354CC2-7D76-44AA-8F31-5386107AE062Q26822002-E88A158D-CE8C-4150-A4D3-A2E899A0AA2EQ28216994-2369E58C-6346-4791-B424-936D619F254AQ28281395-BF8218E4-8C76-423F-B4E2-1E391E6FEE62Q28488690-B714294C-8467-4297-9F92-19F6AB9FD017Q28550062-F7FEC41F-6652-4E2D-999B-C9633EE66347Q28828354-DF1AA1E8-6F34-4A05-9BE5-FD4A62714A45Q30315907-FEF17835-8D31-4BA9-AFFF-E2A0415D09C4Q30319326-8498EBF5-F3EE-4889-9C15-B5C711BC1ED1Q30379691-E90A993E-F0E3-4A6A-9703-F66A792626BEQ30391127-10EE548A-5E71-49D7-817C-247E0779E9BBQ30512697-C5CB398D-3B14-4F2C-8556-6BE7F4DFF895Q30579707-0AFE67CD-F538-4B52-BC28-E5C9E8C6D95BQ30777774-FB55F6E8-984C-4609-8395-1EBA654340C3Q31050722-AB1EBB63-DB28-44AD-8FD6-9B031F84E526Q31078434-92E04A91-38E7-4889-9529-18C7ABDE7E45Q33221066-74E58BA5-9215-4A61-B637-B95BABCE254FQ33283469-AD071339-488A-41AB-8F58-FEA67D4A0E96Q33699436-4551D3B3-55EC-42B9-A06D-54B5FBCCE016Q33706311-CB9A1565-E47E-4D1D-AC22-7B177078D751Q33742590-37EA976E-522E-4C14-B9C3-7E3918C55F71Q33745216-685A57C6-39A7-4851-BDAD-649C6EBDD7CDQ33801986-95E64503-5B73-452E-87FE-4D847FCB8013Q33808415-9BE8E440-093E-48F1-BD40-A2272B2A8A1FQ33827984-FCDBA60C-A849-4608-AD84-5FF12E79F9AFQ33928434-72759503-91DB-4C29-914B-8907BD8093B3Q33936586-078E9879-B56D-48E2-BA62-1D4EA6D2A158Q34029566-778B0030-FADB-4F98-B98F-1320AE227A96Q34221510-45622C8B-824E-4A8B-965F-12B43956672D
P2860
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
name
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@ast
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@en
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@nl
type
label
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@ast
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@en
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@nl
prefLabel
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@ast
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@en
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@nl
P2093
P2860
P3181
P356
P1476
beta-Amyloid-(1-42) is a major ...... pathology of Alzheimer disease
@en
P2093
J D Lowenson
R J Cotter
P2860
P304
P3181
P356
10.1073/PNAS.90.22.10836
P407
P577
1993-11-15T00:00:00Z